FDA Investor Relations: SEC Agreement Close, “Complete Response” Reg Not
Executive Summary
FDA's role in policing investor communications about regulatory actions will continue to receive attention in 2004 after the Securities & Exchange Commission opened investigations into Biopure and Amylin
You may also be interested in...
Biopure Disclosure Policies To Be Reviewed Under Hemopure SEC Settlement
Biopure must undergo a review of its disclosure, compliance and other securities policies as part of a settlement with the Securities & Exchange Commission over alleged misrepresentations concerning its investigational synthetic blood product Hemopure
Biopure Disclosure Policies To Be Reviewed Under Hemopure SEC Settlement
Biopure must undergo a review of its disclosure, compliance and other securities policies as part of a settlement with the Securities & Exchange Commission over alleged misrepresentations concerning its investigational synthetic blood product Hemopure
FDA Regulatory Agenda Includes “Complete Response” Rule, E-Drug Listing
A notice of proposed rulemaking for FDA's "complete response" regulation is scheduled for publication in July, according to HHS' semiannual regulatory agenda published in the June 28 Federal Register